Andere Kunden interessierten sich auch für
![C1040T do inibidor da fibrinólise activada pela trombina]( "C1040T do inibidor da fibrinólise activada pela trombina")
C1040T do inibidor da fibrinólise activada pela trombina29,99 €![C1040T de l¿inhibiteur de fibrinolyse activé par la thrombine]( "C1040T de l¿inhibiteur de fibrinolyse activé par la thrombine")
C1040T de l¿inhibiteur de fibrinolyse activé par la thrombine29,99 €![C1040T dell'inibitore della fibrinolisi attivato dalla trombina]( "C1040T dell'inibitore della fibrinolisi attivato dalla trombina")
C1040T dell'inibitore della fibrinolisi attivato dalla trombina29,99 €![C1040T ingibitora fibrinoliza, aktiwiruemogo trombinom]( "C1040T ingibitora fibrinoliza, aktiwiruemogo trombinom")
C1040T ingibitora fibrinoliza, aktiwiruemogo trombinom13,99 €![C1040T des thrombinaktivierten Fibrinolysehemmers]( "C1040T des thrombinaktivierten Fibrinolysehemmers")
C1040T des thrombinaktivierten Fibrinolysehemmers43,90 €![The 4G/5G polymorphism in the PAI-1 inhibitor gene]( "The 4G/5G polymorphism in the PAI-1 inhibitor gene")
The 4G/5G polymorphism in the PAI-1 inhibitor gene29,99 €![Activity of the Novel BCR Kinase Inhibitor IQS019 in B-NHL]( "Activity of the Novel BCR Kinase Inhibitor IQS019 in B-NHL")
Activity of the Novel BCR Kinase Inhibitor IQS019 in B-NHL23,99 €
Cerebral venous thrombosis (CVT) is defined as thrombus obstruction of a cerebral venous sinus. Factor V leiden (FVL) mutation and thrombin-activatable fibrinolysis inhibitor (TAFI) polymorphism are two key factors in the coagulation and fibrinolysis process involved in the development of thromboembolic diseases. However, the role of these factors in the development of DVT remains ambiguous. The aim of this study was to determine the imputability of the FVL mutation and the TAFIC1040T polymorphism in the occurrence of DVT in young people. Through a case-control study including 32 patients and 49 controls collected at the neurology department of CHU Habib Bourguiba Sfax. The molecular study showed that 37.5% of our patients were heterozygous for the C1040T mutation and 12.5% were homozygous mutants. This study also showed that there was a significant association between the TAFI C1040T polymorphism and the risk of CVT.